|Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation|
Antimicrobial Agents and Chemotherapy
American Society for Microbiology.
|Mukaide, M; Tanaka, Y; ShinI, T; Yuen, MF; Kurbanov, F; Yokosuka, O; Sata, M; Karino, Y; Yamada, G; Sakaguchi, K; Orito, E; Inoue, M; Baqai, S; Lai, CL; Mizokami, M||2010||243|
|Three-year assessment of entecavir resistance in chronic hepatitis B patients and the mechanism of viral breakthrough by the resistance substitutions|
John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
|Tanaka, Y; Mukaide, M; Yuen, RMF; Shin, IT; Orito, E; Kurbanov, F; Fukai, K; Yokosuka, O; Sata, M; Ide, T; Karino, Y; Yamada, G; Sakaguchi, K; Inoue, M; Gish, RG; Lai, CL; Mizokami, M||2008||223|
|A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C|
Blackwell Publishing Ltd.
|Orito, E; Fujiwara, K; Tanaka, Y; Yuen, MF; Lai, CL; Kato, T; Sugauchi, F; Kusakabe, A; Sata, M; Okanoue, T; Niitsuma, H; Sakugawa, H; Hasegawa, I; Mizokami, M||2006||152|